Researchers examined interest in MC1R testing in the general population and assessed patterns across demographic and skin cancer risk factors.
Researchers assessed the effect intake levels of folate and other nutrients involved in one-carbon metabolism have on risk of melanoma.
Systemic review and meta-analysis evaluated the efficacy of nivolumab vs ipilimumab, in combination, as monotherapy, or vs other treatment options for the treatment of metastatic melanoma.
Researchers sought to determine if melanoma risk was associated with oral contraceptive use or if OC users are more likely to have higher exposure to UV light.
Approval was granted for the treatment of patients with unresectable or metastatic BRAF V600E or V600K mutation-positive melanoma.
Study data indicate that checkpoint inhibitors combined with radiation could improve survival for patients with melanoma-related brain metastases.
Greater reproducibility and higher concordance for melanoma staging observed with implementation of AJCC 8.
Using data from the NHS and the HPFS, researchers investigated the association between polyunsaturated fat, cholesterol, and monounsaturated fat intake and risks for SCC, melanoma, and BCC.
After adjusting for confounding factors,a significantly decreased risk for subsequent AD was reported among patients with malignant melanoma.
In this phase 2 study, researchers randomly assigned 79 patients with immunotherapy-naive melanoma with brain metastases to receive either nivolumab plus ipilimumab or nivolumab alone.
In a review of nearly 200,000 patients from a Midwest metropolitan area, researchers sought to determine if chronic aspirin use would offer the same risk reduction for melanoma as has been seen in various cancers.
A cross-sectional analysis evaluated the impact of hope and optimism on different facets of psychological distress among patients with advanced melanoma, colorectal, lung, or gastrointestinal cancers.
Investigators sought to compare the prognostic value of sentinel lymph node status vs Breslow thickness in patients with cutaneous melanoma.
The likelihood for development of cutaneous melanoma may be greater for individuals with iris pigmented lesions, according to a study.
Investigators sought to evaluate whether age is associated with risk for immune-related adverse events among patients with metastatic melanoma treated with immunotherapy.
Researchers report on finding of a double-blind phase 3 study on the efficacy of adjuvant vemurafenib in patients with resected stage IIC to IIIB melanoma.
iPSC vaccine prevented tumor growth in syngeneic murine breast CA, mesothelioma, melanoma models
A retrospective study evaluated the relationship of BMI with survival outcomes among patients with metastatic melanoma who received targeted therapy, immunotherapy, or chemotherapy.
The FDA granted approval for nivolumab for adjuvant treatment of some patients with melanoma, based on the results of the CHECKMATE-238 study.
Baseline tumor size and PD-L1 status were independently associated with the likelihood of a complete response.
Patients presenting with lesions with shiny white streaks on dermoscopy should undergo biopsy for possible melanoma.
Melatonin and its analogues, in addition to their ability to regulate circadian rhythms, may exhibit cytotoxic activity via various cellular mechanisms.
An increased prevalence of melanoma has been observed in patients with various immunocompromised conditions.
Individuals categorized as overweight or obese had a significantly increased risk for malignant melanoma.
Fifty-five percent of patients treated with pembrolizumab survived through 24-months compared with 43% of patients treated with ipilimumab.
[Cancer Management and Research] This study examines the advances that pembrolizumab has made in melanoma and upcoming research that may further improve melanoma treatment.
Case Report of a KIT-mutated Melanoma Patient With an Excellent Response to Apatinib and Temozolomide Combination TherapyOctober 20, 2017
[OncoTargets and Therapy] This article examines a case of metastatic melanoma in which the patient had an excellent response to apatinib/TMZ combination therapy with progression-free survival for more than one year.
Median overall survival from time of diagnosis has increased from 7.5 to 22.7 months in the last decade.
Overall survival was significantly prolonged in patients with advanced melanoma who were treated with nivolumab plus ipilimumab compared with either drug alone, according to results from the Checkmate 067 study.
A study on a cohort of women enrolled in the WHI-OS shows that those with a history of periodontal disease had a higher risk for developing some cancers.
Sign Up for Free e-newsletters
- Study Finds Association Between Folate Intake and Risk of Cutaneous Melanoma
- Melanoma Outcomes Improved With Nivolumab Alone or Plus Ipilimumab
- Oral Contraceptive Use May Not Be Associated With Increased Melanoma Risk
- The Caregivers' Cancer Journey
- Staff Education Leads to Increase in Oncology Rehabilitation Referrals
- Implementing an Ambulatory Adherence Program May Improve Oral Anticancer Medications Compliance
- Exercise Habits Influence Mortality in Adult Survivors of Childhood Cancer
- Managing Dyspnea With Fentanyl in Patients With Cancer at End of Life
- CALM: A Depression Intervention for Cancer Patients at the End of Life
- High BMI Among Premenopausal Women May Improve Risk for Breast Cancer
- Choice of Breast Reconstruction After Mastectomy Affects Satisfaction, Quality of Life
- Gender Bias in Medicine Has Far-Reaching Consequences
- Carfilzomib Benefits May Outweigh Cardiovascular Risk in Multiple Myeloma
- Patient Interest in Melanoma Genetic Risk Testing is Fairly High
- Genetic Link Between Depression and Breast Cancer Remains Unclear
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|